Kymera Therapeutics, Inc. (KYMR) Stock Price & Analysis

Kymera Therapeutics, Inc. (KYMR) closed at USD 110.85 on Thursday, October 22, 2026, down 1.58% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 112.63; the Oct 22, 2026 session ranged USD 110.16–113.73 on volume of 850,259 shares. Market capitalization is $9.12B, with a 52-week range of USD 55.26–130.05 (NGM). Source: Nexqual, retrieved October 23, 2026 at 10:04 UTC.

Also available as compact Markdown for AI agents: nexqual.com/KYMR.md

Key facts (KYMR)

• Last four reported quarters (through Jun 30, 2026): revenue $105M, net income -$300M (-285.3% margin), free cash flow -$238M (SEC filings).
• Insider open-market sales, last ~7 months: 24 Form 4 filings, $397M; 2 not under a Rule 10b5-1 plan ($174M); 8 by opportunistic insiders (0 outside 10b5-1 plans), 1 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 1.88 on a 1–5 scale) (24 analysts), mean target USD 139.35 (range 111–180).
• Total return with dividends: 1Y +91.9% vs S&P 500 +14.9%; 5Y +99.1% vs S&P 500 +80.3%.
• Next earnings: 2026-10-29, EPS estimate USD -1.27, revenue estimate $2.9M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (KYMR)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (KYMR)

P/S 86.8x · P/B 6.0x · FCF yield -2.61% · Earnings yield -3.29%

Insider sales (SEC Form 4, open-market, last ~7 months) (KYMR)

22 of 24 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (KYMR)

Consensus Buy (mean 1.88 on a 1–5 scale), 24 analysts; mean target USD 139.35 (low 111, high 180).

Rating changes, last 120 days:

Total return (dividends reinvested) (KYMR)

KYMR suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 26, 2026.

Companies that name KYMR in their SEC reports

KYMR company outlook (results filed Aug 5, 2026)

• “The accelerated timeline enables us to pull forward our expected topline readout to year-end 2026, positions us for an earlier than anticipated start to Phase 3 trials next year, and ultimately allows us to move faster for patients who are waiting for new options." Dr.”
• “The earlier than expected completion of enrollment enabled the Company to accelerate its expected topline data readout by six months to year-end 2026, earlier than prior guidance to share data by mid-2027.”
• “Subject to discussions with regulators, the Company expects to initiate Phase 3 trials in AD by mid-2027. • Enrollment is ongoing in the KT-621 BREADTH Phase 2b clinical trial in patients with moderate to severe eosinophilic asthma.”
• “The Company expects to report data in late 2027. • In June 2026 at the Japanese Dermatological Association (JDA) Annual Meeting, the Company presented results from the KT-621 Phase 1 study in healthy Japanese adults designed to support the enrollment of patients in Japan in global KT-621 studies.”

Quoted word-for-word from the SEC 8-K results press release.

KYMR analyst estimates and revisions

KYMR options: expected move

Options price a move of about ±24.6% (±$27.25) by Nov 20, 2026, which includes earnings on Oct 29, 2026. Over the last 8 reports the stock moved ±3.1% on average.

30-day implied volatility 109.6% vs 40.3% realized over the last 30 trading days. Put/call ratio (volume) 1.6. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 10:04 UTC)

Technical Analysis (KYMR)

Nexqual's technical model rates KYMR "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 10:04 UTC.

Analyst Ratings (KYMR)

Wall Street analysts rate KYMR "Buy" based on 24 analysts, with a mean price target of USD 139.35 (range USD 111–180), per Nexqual as of October 23, 2026 at 10:04 UTC.

Earnings (KYMR)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 10:04 UTC.

Financials & Fundamentals (KYMR)

Source: Nexqual, October 23, 2026 at 10:04 UTC.

Financial Health Score (KYMR)

Nexqual rates Kymera Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 10:04 UTC.

Ownership (KYMR)

Source: Nexqual, October 23, 2026 at 10:04 UTC.

Leadership (KYMR)

Kymera Therapeutics, Inc. is led by Nello Mainolfi, Co-Founder, President, CEO & Director, per Nexqual as of October 23, 2026 at 10:04 UTC.

Major Backers & Investors (KYMR)

Notable institutional backers of Kymera Therapeutics, Inc. include FMR, LLC, Baker Bros. Advisors, LP, Avoro Capital Advisors LLC, according to Nexqual as of October 23, 2026 at 10:04 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 10:04 UTC.

From Kymera Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Our approach to target selection and our proprietary drug discovery capabilities enable us to rationally design innovative medicines that ultimately have the potential to address disease-causing proteins of all classes.
• We have developed a broad patent estate and expect to expand and protect our proprietary know-how and intellectual property.
• We seek to protect our proprietary technology, in part, through confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and potential collaborators.
• Our success also depends on our ability to defend and enforce our intellectual property rights, preserve the confidentiality of our proprietary information, and operate without infringing, misappropriating or otherwise violating the valid and enforceable patents and proprietary rights of third parties.

Partnerships

• On November 15, 2022, we entered into an Amended and Restated Collaboration and License Agreement with Sanofi, or the Amended Sanofi Agreement, which amended the Original Sanofi Agreement to revise certain research terms and responsibilities set forth under the Original Sanofi Agreement.
• In June 2025, we announced a strategic collaboration with Gilead Sciences, Inc. ("Gilead") to develop novel oral molecular glue degraders for CDK2.

Legal & Regulatory Risks (Item 1A, quoted)

• Risks Related to Preclinical and Clinical Development
• We may not be successful in our efforts to identify or discover additional product candidates or we may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
• We currently have no product candidates approved for sale and may never be able to develop marketable product candidates.
• Any of these factors, many of which are beyond our control, could jeopardize our ability to obtain regulatory approval for and successfully market our current or future product candidates.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:04 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt